Balancing Risk, Cost, and Access: Early Access Programmes and Competing Policy Objectives in the EU

View at publisher Summarise with VIRAT
Authors: Miquel Díaz Hernández
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Early access is an exception to the general pharmaceutical marketing authorisation procedure that allows for market access in an early stage of development. The criteria for access revolve around the concept of ‘unmet medical need’, which indicates its exceptional character. Its key component is the multitude of actors and policy objectives, whose hierarchy is inverted in relation to the usual circumstances. In parallel, the distribution of competences between Member States and the Union are slightly shifted. This article explores, using early access as the golden middle example, whether the hierarchisation of policy objectives affects the distribution of competences between Member States and the Union, all of this while underlining the potential early access has in the new Pharma Package both independently and as a potential tool of the upcoming sandbox regulatory model.

Fields of Study & Subjects

Healthcare Regulation Biomedical Ethics and Regulation Pharmaceutical Economics and Policy

Publication details

Journal / source
European Health & Pharmaceutical Law Review
Volume
9
Issue
1
Pages
19–31
Publication date
1 January 2026
Language
EN